FDA and the HHS Office of Inspector General are butting heads over whether the agency is equipped to address postmarket cybersecurity risks to medical devices. A report released by the OIG last month says FDA has a long way to go on addressing such risks, pointing out a lack of written procedures for handling cybersecurity events, for sharing information between stakeholders, and for recalling vulnerable devices, as well as a lack of testing of the agency’s ability to respond to...